Castle Biosciences Stock Net Income
| CSTL Stock | USD 24.33 1.49 6.52% |
Castle Biosciences fundamentals help investors to digest information that contributes to Castle Biosciences' financial success or failures. It also enables traders to predict the movement of Castle Stock. The fundamental analysis module provides a way to measure Castle Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Castle Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -75.5 M | -71.7 M | |
| Net Loss | -60.4 M | -57.4 M | |
| Net Loss | -57.5 M | -54.6 M | |
| Net Loss | (2.14) | (2.25) | |
| Net Income Per E B T | 1.00 | 1.07 |
Castle | Net Income |
Castle Biosciences Company Net Income Analysis
Castle Biosciences' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Castle Biosciences Net Income | (57.47 M) |
Most of Castle Biosciences' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Castle Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Castle Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Castle Biosciences is extremely important. It helps to project a fair market value of Castle Stock properly, considering its historical fundamentals such as Net Income. Since Castle Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Castle Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Castle Biosciences' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Castle Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Castle Biosciences reported net income of (57.47 Million). This is 116.84% lower than that of the Biotechnology sector and 133.2% lower than that of the Health Care industry. The net income for all United States stocks is 110.06% higher than that of the company.
Castle Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Castle Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Castle Biosciences could also be used in its relative valuation, which is a method of valuing Castle Biosciences by comparing valuation metrics of similar companies.Castle Biosciences is currently under evaluation in net income category among related companies.
Castle Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Castle Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Castle Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Castle Biosciences' value.| Shares | Geode Capital Management, Llc | 2023-12-31 | 566.1 K | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 547.4 K | Kornitzer Capital Management Inc | 2023-12-31 | 542.9 K | Palisade Capital Management Llc | 2023-12-31 | 539.1 K | Citadel Advisors Llc | 2023-09-30 | 518.1 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 478 K | Parkman Healthcare Partners Llc | 2023-12-31 | 357.2 K | Intrinsic Edge Capital Management, Llc | 2023-12-31 | 326.3 K | Ameriprise Financial Inc | 2023-12-31 | 279.7 K | Wasatch Advisors Lp | 2023-12-31 | 2.6 M | Blackrock Inc | 2023-12-31 | 2.3 M |
Castle Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0943 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 399.26 M | ||||
| Shares Outstanding | 27.59 M | ||||
| Shares Owned By Insiders | 3.03 % | ||||
| Shares Owned By Institutions | 89.07 % | ||||
| Number Of Shares Shorted | 1.46 M | ||||
| Price To Earning | 87.86 X | ||||
| Price To Book | 1.41 X | ||||
| Price To Sales | 2.52 X | ||||
| Revenue | 219.79 M | ||||
| Gross Profit | 105.03 M | ||||
| EBITDA | (55.65 M) | ||||
| Net Income | (57.47 M) | ||||
| Cash And Equivalents | 273.17 M | ||||
| Cash Per Share | 10.39 X | ||||
| Total Debt | 15.31 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 11.08 X | ||||
| Book Value Per Share | 14.27 X | ||||
| Cash Flow From Operations | (135 K) | ||||
| Short Ratio | 7.73 X | ||||
| Earnings Per Share | (2.14) X | ||||
| Target Price | 33.11 | ||||
| Number Of Employees | 610 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 630.09 M | ||||
| Total Asset | 477.81 M | ||||
| Retained Earnings | (218.37 M) | ||||
| Working Capital | 247.97 M | ||||
| Current Asset | 125.89 M | ||||
| Current Liabilities | 13.31 M | ||||
| Net Asset | 477.81 M |
About Castle Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Castle Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Castle Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Castle Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Castle Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Castle Biosciences' short interest history, or implied volatility extrapolated from Castle Biosciences options trading.
Pair Trading with Castle Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Castle Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Castle Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Castle Stock
| 0.69 | EDSA | Edesa Biotech Financial Report 9th of May 2024 | PairCorr |
Moving against Castle Stock
| 0.66 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.57 | GBIO | Generation BioCo Financial Report 8th of May 2024 | PairCorr |
| 0.46 | VTYX | Ventyx Biosciences Financial Report 9th of May 2024 | PairCorr |
| 0.45 | LYRA | Lyra TherapeuticsInc Financial Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Castle Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Castle Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Castle Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Castle Biosciences to buy it.
The correlation of Castle Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Castle Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Castle Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Castle Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Castle Biosciences Piotroski F Score and Castle Biosciences Altman Z Score analysis. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Castle Stock analysis
When running Castle Biosciences' price analysis, check to measure Castle Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Castle Biosciences is operating at the current time. Most of Castle Biosciences' value examination focuses on studying past and present price action to predict the probability of Castle Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Castle Biosciences' price. Additionally, you may evaluate how the addition of Castle Biosciences to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Castle Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share (2.14) | Revenue Per Share 8.2 | Quarterly Revenue Growth 0.725 | Return On Assets (0.09) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.